CSL
Online/Digital
The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. Over the ensuing years, CSL provided Australians with rapid access to 20th-century medical advances including insulin and penicillin, and vaccines against influenza, polio, and other infectious diseases. CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994.
Since then, CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotechnology leader CSL Behring; U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma; the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second-largest influenza vaccines company; Calimmune, a leader in gene-modification and cell delivery technology; and Vitaeris, a biopharmaceutical company focused on the development of canakinumab as a potential treatment option for organ transplant recipients experiencing rejection. Their combined and rich histories make CSL the innovative global leader it is today.
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | Australia |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesLancet publication marks important advance in influenza prevention for older adults
Intended for healthcare, medical and scientific media and investors Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.
CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing
Agreements support lower prices for CSL therapies and reflect CSL's $1.5 billion plan to expand its U.S. manufacturing capacity in Illinois KING OF PRUSSIA, Pa., - August 31, 2026 – CSL (ASX:CSL; USOTC:CSLLY) today announces agreements with the U.S. government to lower the cost of medicines in the U.S., reflecting CSL’s previously announced plan to expand its plasma therapy production capacity in Kankakee, Illinois.
European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries
ST. GALLEN, SWITZERLAND – 6 August, 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Commission (EC) has adopted the decision revoking the marketing authorisation for TAVNEOS® (avacopan). This decision follows the recommendation made by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) on 26 June 2026.
A further update on TAVNEOS® (avacopan) in the European Union
Dear ANCA‑associated vasculitis community, Further to our last update regarding TAVNEOS® (avacopan), we wanted to inform you that the European Commission (EC) has adopted a decision revoking the marketing authorisation for TAVNEOS in the European Union (EU) and European Economic Area (EEA) countries. While we are disappointed by the decision resulting from the Article 20 procedure, we respect the outcome of the regulatory process and are committed to implementing it in full. What happens now?
5 Things to Know About Clinical Trials for Children
Children who have rare and serious diseases are often treated with medicines that were developed and tested in adults. For those whose young lives are affected by serious health problems, clinical trials may provide early access to potential treatments that could alleviate symptoms and contribute to critical data on how children will respond to treatment. It’s a big decision to participate in a clinical trial.
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress , /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE).
Safeguarding the Economic Viability of Critical Medicines in Europe
The European Union Critical Medicines List and the Critical Medicines Act haveidentified plasma-derived medicinal products, such as immunoglobulins, as “critical medicines” because of the seriousness of the diseases they address and the lack of suitable alternatives. Plasma-derived medicines are made from donated human plasma and require complex processing called fractionation to isolate essential proteins.
An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Supply and Patient Access
Dear Hemophilia B Community, In March, we shared an update regarding HEMGENIX® (etranacogene dezaparvovec-drlb) availability and our efforts to support people living with hemophilia B while maintaining the highest quality standards for this one-time gene therapy. Since then, we have provided monthly updates to healthcare professionals and patient organizations to enable them to support patient care.
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union (EU) marketing authorisation for TAVNEOS® (avacopan).
Our commitment to continued support for the ANCA Associated Vasculitis Community
Dear ANCA‑associated vasculitis community, We are writing to share an important update on TAVNEOS® (avacopan) in the European Union (EU). The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the EU marketing authorisation for TAVNEOS. The CHMP opinion has been provided to the European Commission (EC), and a final decision by the EC is expected shortly.